Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

Eichhorn, Florian ; Klotz, Laura V. ; Bischoff, Helge ; Thomas, Michael ; Lasitschka, Felix ; Winter, Hauke ; Hoffmann, Hans ; Eichhorn, Martin E.

In: BMC Cancer, 19 (2019), Nr. 413. pp. 1-8. ISSN 1471-2407

[thumbnail of 12885_2019_Article_5624.pdf] PDF, English - main document
Download (2MB) | Lizenz: Creative Commons LizenzvertragNeoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial by Eichhorn, Florian ; Klotz, Laura V. ; Bischoff, Helge ; Thomas, Michael ; Lasitschka, Felix ; Winter, Hauke ; Hoffmann, Hans ; Eichhorn, Martin E. underlies the terms of Creative Commons Attribution 4.0

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Abstract Background Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim of the NEOMUN investigator initiated trial (EudraCT-Number: 2017–000105-20; ClinicalTrials.gov Identifier: NCT03197467) is to assess feasibility and safety of pre-surgical anti PD-1 treatment in order to improve long term survival. Methods The study is designed as an open-label, single arm, prospective, monocenter, phase II study including 30 patients with NSCLC stage II/IIIA suitable for curative intent surgery. Investigational drug is Pembrolizumab. After 2 cycles of immunotherapy (à 200 mg q3w i.v.), tumor resection with lobectomy or bilobectomy will be performed. Primary objectives are to assess the feasibility and safety of a neoadjuvant immunotherapy and to assess antitumor activity of Pembrolizumab with regard to clinical and pathological tumor response. Secondary objective is disease free and overall survival. Exploratory objective is to analyze potential predictive biomarkers and to evaluate the therapeutic efficacy of Pembrolizumab by extended immune cell and cytokine analysis of tumor tissue. The study protocol was approved by the local ethics committee and the federal authority. Start of patient enrollment is scheduled for June 2018. Discussion The NEOMUN trial will be one of the first clinical trials investigating a multimodal treatment strategy including neoadjuvant immunotherapy using Pembrolizumab as an investigational drug. Assessing the safety and therapeutic potential of neoadjuvant immunotherapy in connection with lung surgery will be of great interest for thoracic surgeons. Trial registration Prospectively, the NEOMUN study has been registered on www.clinicaltrials.gov ; NCT03197467 (first post: June 23rd, 2017).

Document type: Article
Journal or Publication Title: BMC Cancer
Volume: 19
Number: 413
Publisher: BioMed Central ; Springer
Place of Publication: London ; Berlin, Heidelberg
Date Deposited: 24 Jul 2019 13:58
Date: 2019
ISSN: 1471-2407
Page Range: pp. 1-8
Faculties / Institutes: Medizinische Fakultät Heidelberg > Pathologisches Institut
Medizinische Fakultät Heidelberg > Thoraxklinik Heidelberg gGmbH
DDC-classification: 610 Medical sciences Medicine
Uncontrolled Keywords: NSCLC, Neoadjuvant immunotherapy, Checkpoint inhibitor, Thoracic surgery, Pembrolizumab
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative